Bolt Biotherapeutics, Inc. (BOLT) stock
BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/305% below fair value
$5.10−0.55 (-9.73%)
Close on Nov 18, 2026Market cap $9.82MP/E –Yield –
Bolt Biotherapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Bolt Biotherapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$39.92M. For fiscal 2025 it was -$39.92M. The highest annual figure on record is -$39.92M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$39.92M | – |
| FY2024 | Dec 31, 2024 | -$61.33M | – |
| FY2023 | Dec 31, 2023 | -$69.73M | – |
| FY2022 | Dec 31, 2022 | -$78.46M | – |
| FY2021 | Dec 31, 2021 | -$59.40M | – |
| FY2020 | Dec 31, 2020 | -$50.57M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$3.08M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.16M | – |
| Q3 FY2025 | Sep 30, 2025 | -$9.80M | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.43M | – |
| Q3 FY2024 | Sep 30, 2024 | -$14.01M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.14M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.75M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.27M | – |
| Q3 FY2023 | Sep 30, 2023 | -$16.91M | – |
| Q2 FY2023 | Jun 30, 2023 | -$15.14M | – |
| Q1 FY2023 | Mar 31, 2023 | -$23.40M | – |
| Q4 FY2022 | Dec 31, 2022 | -$18.14M | – |
| Q3 FY2022 | Sep 30, 2022 | -$14.19M | – |
| Q2 FY2022 | Jun 30, 2022 | -$21.22M | – |
| Q1 FY2022 | Mar 31, 2022 | -$24.92M | – |
| Q4 FY2021 | Dec 31, 2021 | -$18.36M | – |
| Q3 FY2021 | Sep 30, 2021 | -$19.74M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.69M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.62M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.79M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.67M | – |
| Q2 FY2020 | Jun 30, 2020 | -$13.11M | – |
| Q1 FY2020 | Mar 31, 2020 | -$10.01M | – |
See a number that looks wrong?